Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection

NCT01780831 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Raltegravir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)